InflaRx NV (InflaRx NV) Gross Profit : $-0.71 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Gross Profit?

InflaRx NV's gross profit for the three months ended in Mar. 2024 was $-0.20 Mil. InflaRx NV's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.71 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. InflaRx NV's gross profit for the three months ended in Mar. 2024 was $-0.20 Mil. InflaRx NV's Revenue for the three months ended in Mar. 2024 was $0.04 Mil. Therefore, InflaRx NV's Gross Margin % for the quarter that ended in Mar. 2024 was -512.82%.

InflaRx NV had a gross margin of -512.82% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

During the past 9 years, the highest Gross Margin % of InflaRx NV was -666.98%. The lowest was -740.58%. And the median was -740.58%.

InflaRx NV Gross Profit Historical Data

The historical data trend for InflaRx NV's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Gross Profit Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Profit

Get a 7-Day Free Trial

-0.51

InflaRx NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross Profit	Get a 7-Day Free Trial															-	-	-0.21	-0.30	-0.20

Competitive Comparison of InflaRx NV's Gross Profit

For the Biotechnology subindustry, InflaRx NV's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Gross Profit distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Gross Profit falls into.

InflaRx NV Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

InflaRx NV's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	0.069	-	0.58
	=	-0.51

InflaRx NV's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )	=	Revenue	-	Cost of Goods Sold
	=	0.039	-	0.239
	=	-0.20

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.71 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

InflaRx NV's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )	=	Gross Profit (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	-0.20	/	0.039
	=	-512.82 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

InflaRx NV (NAS:IFRX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

InflaRx NV had a gross margin of -512.82% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

InflaRx NV Gross Profit Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Gross Profit

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.